<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "https://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" dtd-version="1.2" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">IJMABHR</journal-id>
<journal-title-group><journal-title>International Journal of Medical and All Body Health Research</journal-title><abbrev-journal-title>IJMABHR</abbrev-journal-title></journal-title-group>
<issn pub-type="epub">2582-8940</issn>
<publisher><publisher-name>Anfo Publication House</publisher-name></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">320</article-id>
<article-id pub-id-type="doi">10.54660/IJMBHR.2022.3.1.83-86</article-id>
<title-group><article-title>Extended-Release Formulations of Safer Opioids: Improving Adherence and Reducing Mental Health Burdens</article-title></title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes"><name><surname>Ameh</surname><given-names>Sunday</given-names></name><xref ref-type="aff" rid="aff1"/></contrib>
<contrib contrib-type="author"><name><surname>Asogwa</surname><given-names>Kelechi</given-names></name><xref ref-type="aff" rid="aff1"/></contrib>
<contrib contrib-type="author"><name><surname>Awojulu</surname><given-names>Taiwo</given-names></name><xref ref-type="aff" rid="aff1"/></contrib>
<contrib contrib-type="author"><name><surname>Oturu</surname><given-names>Oscar</given-names></name><xref ref-type="aff" rid="aff2"/></contrib>
<contrib contrib-type="author"><name><surname>Ezeani</surname><given-names>Joseph</given-names></name><xref ref-type="aff" rid="aff3"/></contrib>
<aff id="aff1"><label>1</label>University of Benin, Benin City, Edo PMB, Nigeria</aff>
<aff id="aff2"><label>2</label>University of Jos, Jos, Plateau State, PMB, Nigeria</aff>
<aff id="aff3"><label>3</label>University of Toledo, Toledo, OH, USA</aff>
</contrib-group>
<pub-date publication-format="electronic" date-type="pub"><year>2022</year></pub-date>
<volume>3</volume>
<issue>1</issue>
<fpage>83</fpage>
<lpage>86</lpage>
<history>
<date date-type="received"><day>08</day><month>01</month><year>2022</year></date>
<date date-type="accepted"><day>01</day><month>02</month><year>2022</year></date>
</history>
<permissions><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-sa/4.0/?utm"><license-p>CC BY-NC-SA 4.0</license-p></license></permissions>
<self-uri xlink:href="https://www.allmedicaljournal.com/article/320/extended-release-formulations-of-safer-opioids-improving-adherence-and-reducing-mental-health"/>
<self-uri content-type="pdf" xlink:href="https://www.allmedicaljournal.com/article/320/download"/>
<abstract><p>The opioid crisis remains a significant public health challenge, with opioid misuse, dependence, and mental health comorbidities posing serious concerns for patients and healthcare providers alike. Extended-release (ER) formulations of opioids have been developed as a means to provide stable analgesia while mitigating risks associated with immediate-release (IR) formulations. This paper critically examines how ER formulations of safer opioids can enhance medication adherence, reduce withdrawal symptoms, minimize abuse potential, and lower the mental health burdens associated with opioid use and misuse. The analysis is based exclusively on research findings published, ensuring a historical perspective on the evolution of ER opioid formulations and their clinical implications.</p></abstract>
<kwd-group kwd-group-type="author"><kwd>Extended-release opioids</kwd><kwd>opioid adherence</kwd><kwd>abuse-deterrent formulations</kwd><kwd>opioid crisis</kwd><kwd>mental health</kwd><kwd>pain management</kwd><kwd>opioid misuse</kwd><kwd>pharmacokinetics</kwd></kwd-group>
</article-meta>
</front>
<back><ref-list><title>References</title>
<ref id="R1"><label>1</label><mixed-citation>Almehlisi A, Tainter C. Emergency Medicine Practice. 2019;21(11):1–24.</mixed-citation></ref>
<ref id="R2"><label>2</label><mixed-citation>Anderson D, Zlateva I, Khatri K, Ciaburri N. Using health information technology to improve adherence to opioid prescribing guidelines in primary care. The Clinical Journal of Pain. 2015;31(6):573–579.</mixed-citation></ref>
<ref id="R3"><label>3</label><mixed-citation>Bershad AK, Ruiz NA, De WH. Effects of buprenorphine on responses to emotional stimuli in individuals with a range of mood symptomatology. International Journal of Neuropsychopharmacology. 2018;21(2):120–127.</mixed-citation></ref>
<ref id="R4"><label>4</label><mixed-citation>Bohnert ASB, Ilgen MA. Understanding links among opioid use, overdose, and suicide. The New England Journal of Medicine. 2019;380(1):71–79.</mixed-citation></ref>
<ref id="R5"><label>5</label><mixed-citation>Brady KT, McCauley JL, Back SE. Prescription opioid misuse, abuse, and treatment in the United States: An update. The American Journal of Psychiatry. 2016;173(1):18–26.</mixed-citation></ref>
<ref id="R6"><label>6</label><mixed-citation>Bruera E, Paice JA. Cancer pain management: safe and effective use of opioids. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Meeting. 2015:e593–9.</mixed-citation></ref>
<ref id="R7"><label>7</label><mixed-citation>Butler SF, Cassidy TA, Chilcoat H, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. The Journal of Pain: Official Journal of the American Pain Society. 2013;14(4):351–358.</mixed-citation></ref>
<ref id="R8"><label>8</label><mixed-citation>Candiotti KA, Gitlin MC. Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution? Current Medical Research and Opinion. 2010;26(7):1677–1684.</mixed-citation></ref>
<ref id="R9"><label>9</label><mixed-citation>Carey M, Gospin R, Goyal A, et al. Opioid receptor activation impairs hypoglycemic counterregulation in humans. Diabetes. 2017;66(11):2764–2773.</mixed-citation></ref>
<ref id="R10"><label>10</label><mixed-citation>Cepeda MS, Fife D, Ma Q, Ryan PB. Comparison of the risks of opioid abuse or dependence between tapentadol and oxycodone: results from a cohort study. The Journal of Pain: Official Journal of the American Pain Society. 2013;14(10):1227–1241.</mixed-citation></ref>
<ref id="R11"><label>11</label><mixed-citation>Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Annals of Internal Medicine. 2015;162(4):276–286.</mixed-citation></ref>
<ref id="R12"><label>12</label><mixed-citation>Devulder J, Jacobs A, Richarz U, Wiggett H. Impact of opioid rescue medication for breakthrough pain on the efficacy and tolerability of long-acting opioids in patients with chronic non-malignant pain. British Journal of Anaesthesia. 2009;103(4):576–585.</mixed-citation></ref>
<ref id="R13"><label>13</label><mixed-citation>Dripps IJ, Jutkiewicz EM. Delta opioid receptors and modulation of mood and emotion. Handbook of Experimental Pharmacology. 2018;247:179–197.</mixed-citation></ref>
<ref id="R14"><label>14</label><mixed-citation>Edlund MJ, Martin BC, Russo JE, et al. The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: The role of opioid prescription. The Clinical Journal of Pain. 2014;30(7):557–564.</mixed-citation></ref>
<ref id="R15"><label>15</label><mixed-citation>Gatti A, Gentili M, Baciarello M, et al. Breakthrough pain in patients with controlled or uncontrolled basal pain: an observational study. Journal de la Societe Canadienne pour le Traitement de la Douleur [Pain Research &amp; Management]. 2014;19(6):e168–71.</mixed-citation></ref>
<ref id="R16"><label>16</label><mixed-citation>George B, Minello C, Allano G, et al. Opioids in cancer-related pain: current situation and outlook. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer. 2019;27(8):3105–3118.</mixed-citation></ref>
<ref id="R17"><label>17</label><mixed-citation>Hooten WM, Bruce BK. Beliefs and attitudes about prescribing opioids among healthcare providers seeking continuing medical education. Journal of Opioid Management. 2011;7(6):417–424.</mixed-citation></ref>
<ref id="R18"><label>18</label><mixed-citation>Hwang CS, Kang EM, Ding Y, et al. Patterns of immediate-release and extended-release opioid analgesic use in the management of chronic pain, 2003– 2014. JAMA Network Open. 2018;1(2):e180216.</mixed-citation></ref>
<ref id="R19"><label>19</label><mixed-citation>Iwanicki JL, Severtson SG, McDaniel H, et al. Abuse and diversion of immediate-release opioid analgesics as compared to extended-release formulations in the United States. PLOS ONE. 2016;11(12):e0167499.</mixed-citation></ref>
<ref id="R20"><label>20</label><mixed-citation>Jones MR, Carney MJ, Kaye RJ, et al. Drug formulation advances in extended-release medications for pain control. Current Pain and Headache Reports. 2016;20(6):36.</mixed-citation></ref>
<ref id="R21"><label>21</label><mixed-citation>Kopecky EA, Fleming AB, Levy-Cooperman N, et al. Oral human abuse potential of oxycodone DETERx® (Xtampza® ER). Journal of Clinical Pharmacology. 2017;57(4):500–512.</mixed-citation></ref>
<ref id="R22"><label>22</label><mixed-citation>Kosten TR, Baxter LE. Review article: Effective management of opioid withdrawal symptoms: A gateway to opioid dependence treatment. The American Journal on Addictions. 2019;28(2):55–62.</mixed-citation></ref>
<ref id="R23"><label>23</label><mixed-citation>Manchikanti L, Helm S, Fellows B, et al. Opioid epidemic in the United States. Pain Physician. 2012;15(3 International Journal of Medical and All Body Health Research www.allmedicaljournal.com Suppl):ES9–38.</mixed-citation></ref>
<ref id="R24"><label>24</label><mixed-citation>Martin C, De Baerdemaeker A, Poelaert J, et al. Controlled-release of opioids for improved pain management. Materials Today (Kidlington, England). 2016;19(9):491–502.</mixed-citation></ref>
<ref id="R25"><label>25</label><mixed-citation>Mayock SP, Saim S, Fleming AB. In vitro drug release after crushing: Evaluation of Xtampza® ER and other ER opioid formulations. Clinical Drug Investigation. 2017;37(12):1117–1124.</mixed-citation></ref>
<ref id="R26"><label>26</label><mixed-citation>McLane VD, Bergquist I, Cormier J, Barlow DJ, Houseknecht KL, Bilsky EJ, Cao L. Long-term morphine delivery via slow release morphine pellets or osmotic pumps: Plasma concentration, analgesia, and naloxone-precipitated withdrawal. Life Sciences. 2017;185:1–7.</mixed-citation></ref>
<ref id="R27"><label>27</label><mixed-citation>Morton TL, Devarakonda K, Kostenbader K, Montgomery J, Barrett T, Webster L. Correlation of subjective effects with systemic opioid exposure from fixed-dose combinations of oxycodone/acetaminophen in recreational users of prescription drugs. Pain Medicine. 2016;17(3):539–550.</mixed-citation></ref>
<ref id="R28"><label>28</label><mixed-citation>Paul SM, Allread V. Opioid misuse, abuse and addiction part 2: Opioid prescriber responsibilities and resources. MD Advisor: A Journal for the New Jersey Medical Community. 2017;10(1):4–16.</mixed-citation></ref>
<ref id="R29"><label>29</label><mixed-citation>Pendergrass SA, Crist RC, Jones LK, Hoch JR, Berrettini WH. The importance of buprenorphine research in the opioid crisis. Molecular Psychiatry. 2019;24(5):626– 632.</mixed-citation></ref>
<ref id="R30"><label>30</label><mixed-citation>Pergolizzi JV Jr, Raffa RB, Rosenblatt MH. Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: Current understanding and approaches to management. Journal of Clinical Pharmacy and Therapeutics. 2020;45(5):892–903.</mixed-citation></ref>
<ref id="R31"><label>31</label><mixed-citation>Pergolizzi JV, Raffa RB, Pergolizzi JS, Taylor R. Non-analgesic effects of opioids: Factors relevant to opioid abuse and abuse-deterrent formulations. Current Pharmaceutical Design. 2012;18(37):6109–6115.</mixed-citation></ref>
<ref id="R32"><label>32</label><mixed-citation>Rauck RL. Mitigation of IV abuse through the use of abuse-deterrent opioid formulations: An overview of current technologies. Pain Practice: The Official Journal of World Institute of Pain. 2019;19(4):443–454.</mixed-citation></ref>
<ref id="R33"><label>33</label><mixed-citation>Rogers AH, Zvolensky MJ, Ditre JW, Buckner JD, Asmundson GJG. Association of opioid misuse with anxiety and depression: A systematic review of the literature. Clinical Psychology Review. 2021;84(101978):101978.</mixed-citation></ref>
<ref id="R34"><label>34</label><mixed-citation>Strang J, Volkow ND, Degenhardt L, Hickman M, Johnson K, Koob GF, Marshall BDL, Tyndall M, Walsh SL. Opioid use disorder. Nature Reviews. Disease Primers. 2020;6(1):3.</mixed-citation></ref>
<ref id="R35"><label>35</label><mixed-citation>Vadivelu N, Schermer E, Kodumudi G, Berger JM. The clinical applications of extended-release abuse-deterrent opioids. CNS Drugs. 2016;30(7):637–646.</mixed-citation></ref>
<ref id="R36"><label>36</label><mixed-citation>Webster LR, Markman J, Cone EJ, Niebler G. Current and future development of extended-release, abuse-deterrent opioid formulations in the United States. Postgraduate Medicine. 2017;129(1):102–110.</mixed-citation></ref>
<ref id="R37"><label>37</label><mixed-citation>Yu S, Shen W, Yu L, Hou Y, Han J, Richards HM. Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: A phase 3, randomized, double-blind, multicenter study. The Journal of Pain: Official Journal of the American Pain Society. 2014;15(8):835–844.</mixed-citation></ref>
</ref-list></back>
</article>